Get started

Biotech

McKesson after-hours guidance raiseAfter-hours today, McKesson raised its FY EPS guidance to 14.60-14.80, about 2% above the consensus analyst estimate of 14.41. Its last round of guidance was disappointing, so this reflects a significant improvement in the company's fundamentals. Even though the guidance bump was only 2%, it could catalyze a much larger move in the stock price, which was already trading at a low forward P/E of about 10. Today's guidance implies a forward P/E of more like 9.7 based on today's closing price. McKesson has been in an uptrend anyway, so fortunately for me, I already owned some shares.
NYSE:MCKLong
by ChristopherCarrollSmith
Alexion: Trading around Volume Profile POCIf you like this idea, don't forget to hit the Like Button! Alexion business depends on patent-protected therapies in ultrarare and rare diseases of high unmet medical needs. While competitors are entering the market with biosimilars, Alexion still maintains an essential share of the market. My long term view is bullish. However, from a technical point of view, we are in a critical consolidation phase that started at the end of October 2019. The stock price is consolidating around $107.88 level. What to do now? I would wait for Alexion to exit the consolidation phase with a breakout. My signal is the break of the $116.61 important resistance. Look at the purple line in the graph (Developing POC) to monitor interesting volumes movements able to push up the price (in the chart Developing POC is overlapping the POC red line). I suggest to not go in with a trade immediately after the resistance breakout since Alexion presents high uncertainty. Thus wait for a confirmation green candle (daily). Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
A
by Investing_Fellow
What's The Next Move For DARE? Big news from Bayer and Dare today . Next thing to watch is for FDA approval and then if/when commercialization begins. Until then I think it's still very speculative. HOWEVER. important to note the chart. Last time it traded this high, it remained the case for a few weeks and then plummeted back down to earth. The last time it consistently traded around this price was way back in 2018. So could this mark a new, higher channel or another head fake? "However, the fact remains that a commercialized drug in connection with a company like Bayer isn’t something to ignore. Dare could be entitled to as much as $310 million in milestone payments plus a tiered royalty structure. Does this make it one of the penny stocks to buy right now? That will be determined by the market reaction throughout the week, in my opinion. For now, at least, it seems like one of the penny stocks to watch to start the week." Quote SOURCE: Best Penny Stocks To Watch This Week? 1 Up Over 210% This Year DARE , OTC:BAYRY
NASDAQ:DARE
by PennyStocks101
Alexion finally making movesI've been adding to my Alexion position since December 9, when I posted my previous idea on this stock. The wait is finally paying off, as the stock has surged higher in the past couple days. Alexion is getting unusually bullish call activity today, and the interest is more than justified at this forward P/E of less than 10 and PEG ratio of less than 1. Alexion next reports earnings on February 3, and there are reasons to think it may top Wall Street expectations, including a history of earnings beats and a Zack's ESP of 2.07%. The consensus EPS estimate this quarter is $2.53, but the most accurate estimate is $2.58.
ALong
by ChristopherCarrollSmith
Alexion: Today's opening is confirming the bullish assumptionGood spot for Alexion Pharmaceuticals. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud). I was waiting for today's opening to confirm a bullish position. Furthermore, Alexion trades below its normal Price/Ebitda ratio of 41.13 (currently trading at 11.89). Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
ALong
by Investing_Fellow
Biogen: Further GrowthAfter the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase. I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an exciting phase, testing the high line of the cloud with a bullish configuration, as also confirmed by the Stochastic. The upward trend is also confirmed by fundamental analysis. Biogen counts on a strong collaboration with Roche in oncology, and on growing revenues thanks to Ocrevus (Multiple Sclerosis), as well as to a significant pipeline. Furthermore, the complexity of Biogen's drugs makes the production of Biosimilars difficult. Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:BIIBLong
by Investing_Fellow
Acadia: Stochastic Oscillator UpturnStochastic Oscillator shows upturn for Acadia. Ichimoku Cloud support is very important in this case since today's session is not breaking it and could demonstrate positive trend force. Please note that biotech companies present high uncertainty. Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:ACADLong
by Investing_Fellow
Can SNCA Manage To Break Above Previous ResistanceGreat news and all but can SNCA pull from a technical perspective ? "The patent is for the “Transplantation of human neural cells for treatment of neurodegenerative conditions.” Could this be the next step in developing its NSI-566 treatment? Why I say this is because the treatment is specifically designed around neural stem cells. This is developing as things just began to unfold later in the afternoon. However, it could become one of the penny stocks to watch this month." Source: Are Penny Stocks Profitable? 4 Names To Know Now
S
by PennyStocks101
2
EDIT - EDITAS Genetics time to accumulate and play bounceHello all, Notice MACD, RSI and 50 day MA trends for EDIT. I am planning to accumulate calls this week and some last week to play the bounce signaled by RSI and MACD into the JPM healthcare conference on the 15th where these biotechs present promising results and play pop. Plus biotech is a risky defensive bet - mutually exclusive of Iran - these biotechs are still getting bought out and FDA is approving new drugs like candy.
NASDAQ:EDITLong
by ketokat
CYDY headed toward 1.60 next for wave 5 of I toward stratosphereCytodyn is a 9-year old biotech startup nearing FDA approval for Leronlamib, a humanized monoclonal antibody that's shown no side effects with over 800 AIDS patients through a Phase 3 HIV combo-therapy trial. But Leronlamib is also showing broad efficacy in early trials for HIV monotherapy, HIV prevention, blocking metastasis of many cancers, graft vs host disease, and fatty liver disease (NASH). It was tremendously undervalued until mid-December when it signed an $87 million HIV licensing and commercialization that has stabilized its financing and launched price in a strong up-channel. Submission of BLA application to FDA for HIV combo therapy is imminent in January, which should allow for FDA approval and first sales in 2020. Leronlamib has the potential to transform treatment of several major diseases. Disclosure: I am heavily long.
OTC:CYDYLong
by pythagoras
1